LpxA Inhibitors Targeting ACP Binding Site
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial strategies lack effective targets that are essential for bacterial life, highly conserved in prokaryotes but absent or distinct in humans, with known structures and functions, to develop broad-spectrum antibiotics that interfere with specific bacterial processes without affecting eukaryotic systems.
Innovation Solution
Design and synthesis of novel small molecules targeting the active site of UDP-N-acetylglucosamine acyltransferase (LpxA) and acyl carrier protein (ACP) interactions, using pharmacophore mapping and molecular modeling to inhibit lipid A biosynthesis in gram-negative bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antimicrobial strategies are used, then broad-spectrum antibiotic development is needed, but existing targets are not essential for bacterial life or are present in human cells
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the unique structural features of bacterial ACP (acyl carrier protein) in the lipid A biosynthesis pathway. The pharmacophore model focuses on local interactions at the ACP binding site, exploiting the fact that bacterial ACP has distinct structural characteristics compared to human fatty acid synthase, thereby achieving selectivity without compromising broad-spectrum activity against gram-negative bacteria
Solution Approach 2:
The patent segments the antimicrobial action into two distinct targets: LpxA enzyme and ACP protein. By designing compounds that can inhibit both targets or either target independently, the patent creates a segmented approach to disrupting lipid A biosynthesis, ensuring that essential bacterial functions are blocked while avoiding human cell targets
2Reliability
If lipid A biosynthesis is inhibited, then bacterial growth is stopped and endotoxin levels decrease, but the mechanism must specifically target bacterial enzymes without affecting human systems
Solution Approach 1:
The patent applies preliminary action by using pharmacophore mapping and molecular modeling to pre-design compounds with optimal binding characteristics to ACP and LpxA. This preliminary computational design phase allows researchers to predict active compounds before synthesis, reducing the need for extensive trial-and-error synthesis and testing, thereby simplifying the overall manufacturing process while ensuring safety and efficacy
Solution Approach 2:
The patent uses copying by creating pharmacophore models that represent the essential structural features of known ACP-binding molecules. These models serve as templates for designing new compounds, allowing researchers to copy successful binding motifs from natural products or known inhibitors and adapt them to target bacterial ACP specifically, reducing synthesis complexity while maintaining selectivity
Data Source
AI summary
The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.